High-dose chemotherapy with autologous bone marrow support in advanced XXXX .

@entity1 @entity390 @entity75 @entity391 @entity33 @entity401 @entity320
Eight @entity1 with advanced @entity320 were treated with high-dose melphalan (80-90 mg/m2) and BCNU (600-800 mg/m2). In all @entity1 autologous bone marrow preservation was performed prior to therapy. Bone marrow was stored for 48 h in a refrigerator at 10 degrees C and reinfused 48 h post-therapy. Three @entity1 had a complete response (CR), 1 a partial response and 4 @entity1 no response. Two @entity1 with CR died 4 and 5 months after therapy. One had an @entity401 and 1 @entity1 died from unknown cause. The third @entity1 had a relapse 12 months after therapy. Major side effects were severe @entity390 / @entity391 and a mild @entity33 . Two @entity1 suffered from BCNU-related @entity75 . All @entity1 had a full hematologic reconstitution after 6 weeks. High-dose chemotherapy with autologous bone marrow support achieves a high response rate. Long-term disease-free survival, however, was not seen with this approach.
